Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884750 | 0.91 | KDM4E (0.38) | SMN1; SMN2LMNANPSR1ALDH1A1AKR1C3 | |
| SCHEMBL884614 | 0.91 | LMNA (0.37) | SMN1; SMN2LMNANPSR1ALDH1A1AKR1C3 | |
| SCHEMBL884626 | 0.91 | PKM (0.42) | LMNAALDH1A1POLBCYP2C19USP2 | |
| SCHEMBL884465 | 0.90 | KMT2A (0.37) | SMN1; SMN2LMNANPSR1ALDH1A1AKR1C3 | |
| SCHEMBL885449 | 0.90 | CTSK (0.36) | SMN1; SMN2LMNANPSR1ALDH1A1HPGD | |
| SCHEMBL884467 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNANPSR1ALDH1A1AKR1C3 | |
| SCHEMBL885827 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNANPSR1ALDH1A1AKR1C3 | |
| SCHEMBL884782 | 0.88 | REN (0.38) | LMNANPSR1ALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL2062411 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNANPSR1ALDH1A1POLB | |
| SCHEMBL884320 | 0.87 | LMNA (0.39) | SMN1; SMN2LMNANPSR1ALDH1A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | claimed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | claimed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | claimed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | SMN1; SMN2 4547/4885LMNA 824/4885NPSR1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.